Statins: Cholesterol guidelines and Indian perspective

Statins have become an important drug in preventing the occurrence of atherosclerotic cardiovascular disease (ASCVD). The effectiveness of statins in reducing ASCVD has been established in large-scale clinical trials. The lipid management guidelines have been periodically modified due to accumulatin...

Full description

Bibliographic Details
Main Authors: Anil S Menon, Narendra Kotwal, Yashpal Singh, R Girish
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2015-01-01
Series:Indian Journal of Endocrinology and Metabolism
Subjects:
Online Access:http://www.ijem.in/article.asp?issn=2230-8210;year=2015;volume=19;issue=5;spage=546;epage=553;aulast=Menon
id doaj-5842f44aab0f4d26865e9536128b3abd
record_format Article
spelling doaj-5842f44aab0f4d26865e9536128b3abd2020-11-25T01:36:56ZengWolters Kluwer Medknow PublicationsIndian Journal of Endocrinology and Metabolism2230-82102230-95002015-01-0119554655310.4103/2230-8210.163105Statins: Cholesterol guidelines and Indian perspectiveAnil S MenonNarendra KotwalYashpal SinghR GirishStatins have become an important drug in preventing the occurrence of atherosclerotic cardiovascular disease (ASCVD). The effectiveness of statins in reducing ASCVD has been established in large-scale clinical trials. The lipid management guidelines have been periodically modified due to accumulating evidence about the proportionate benefit achieved with a progressive reduction in cholesterol levels with higher doses of statins and even in those at low risk of development of ASCVD. The current American College of Cardiology/American Heart Association guidelines have based its recommendations from data gathered exclusively from randomized controlled trials. It has simplified the use of statins, but also raised questions regarding the validity of its cardiovascular event risk prediction tool. Epidemiology of cardiovascular disease in India differs from the western population; there is an increased the prevalence of metabolic syndrome and atherogenic dyslipidemia phenotype a group not addressed in the current guidelines. The guidelines are based on trials, which do not have a representative South Asian population. This article reviews the relevant literature, and examines the issues involved in adopting the guidelines to the Indian population.http://www.ijem.in/article.asp?issn=2230-8210;year=2015;volume=19;issue=5;spage=546;epage=553;aulast=MenonAsian Indianslipidsstatins
collection DOAJ
language English
format Article
sources DOAJ
author Anil S Menon
Narendra Kotwal
Yashpal Singh
R Girish
spellingShingle Anil S Menon
Narendra Kotwal
Yashpal Singh
R Girish
Statins: Cholesterol guidelines and Indian perspective
Indian Journal of Endocrinology and Metabolism
Asian Indians
lipids
statins
author_facet Anil S Menon
Narendra Kotwal
Yashpal Singh
R Girish
author_sort Anil S Menon
title Statins: Cholesterol guidelines and Indian perspective
title_short Statins: Cholesterol guidelines and Indian perspective
title_full Statins: Cholesterol guidelines and Indian perspective
title_fullStr Statins: Cholesterol guidelines and Indian perspective
title_full_unstemmed Statins: Cholesterol guidelines and Indian perspective
title_sort statins: cholesterol guidelines and indian perspective
publisher Wolters Kluwer Medknow Publications
series Indian Journal of Endocrinology and Metabolism
issn 2230-8210
2230-9500
publishDate 2015-01-01
description Statins have become an important drug in preventing the occurrence of atherosclerotic cardiovascular disease (ASCVD). The effectiveness of statins in reducing ASCVD has been established in large-scale clinical trials. The lipid management guidelines have been periodically modified due to accumulating evidence about the proportionate benefit achieved with a progressive reduction in cholesterol levels with higher doses of statins and even in those at low risk of development of ASCVD. The current American College of Cardiology/American Heart Association guidelines have based its recommendations from data gathered exclusively from randomized controlled trials. It has simplified the use of statins, but also raised questions regarding the validity of its cardiovascular event risk prediction tool. Epidemiology of cardiovascular disease in India differs from the western population; there is an increased the prevalence of metabolic syndrome and atherogenic dyslipidemia phenotype a group not addressed in the current guidelines. The guidelines are based on trials, which do not have a representative South Asian population. This article reviews the relevant literature, and examines the issues involved in adopting the guidelines to the Indian population.
topic Asian Indians
lipids
statins
url http://www.ijem.in/article.asp?issn=2230-8210;year=2015;volume=19;issue=5;spage=546;epage=553;aulast=Menon
work_keys_str_mv AT anilsmenon statinscholesterolguidelinesandindianperspective
AT narendrakotwal statinscholesterolguidelinesandindianperspective
AT yashpalsingh statinscholesterolguidelinesandindianperspective
AT rgirish statinscholesterolguidelinesandindianperspective
_version_ 1725060709093474304